Skye Bioscience Investors Pressed to Seek Lead Role in Securities Suit as Jan. 16 Deadline Nears

Overview

• The filed class action alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• Plaintiffs claim Skye portrayed nimacimab as more effective than it was and overstated its clinical, regulatory, and commercial prospects.
• Robbins LLP cites an Oct. 6, 2025 topline release reporting a missed primary endpoint and lower-than-expected exposure in a Phase 2a study, after which shares fell 60% to $1.90.
• Several investor law firms, including Rosen, Schall, DJS Law Group, Johnson Fistel, and Robbins, have issued notices urging shareholders to consider lead-plaintiff motions by Jan. 16, 2026.
• The class has not been certified, so investors are not represented unless they retain counsel or a lead plaintiff is appointed.